Study of TNG456 for tumors with MTAP loss
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a confirmed loss of the MTAP gene
- You must be at least 18 years old
- You must be able to swallow pills
- You must have tried standard treatments or they are not right for you
- You must be in fairly good health (able to take care of yourself, up and about more than 50% of the time)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
This trial tests a new drug called CTS3497 in people whose tumors lack a protein called MTAP. The drug aims to stop cancer cells from growing by targeting a weakness caused by this missing protein.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial tests an investigational drug called HSK41959 combined with standard cancer therapy for people whose tumors have a specific genetic change (MTAP deletion). The goal is to see if the combination is safe and works better against advanced solid tumors, including non-small cell lung cancer and pancreatic cancer.
This early-stage trial tests an experimental drug (BGB-58067) for people with a newly diagnosed glioblastoma that has a specific gene deletion (MTAP). It aims to see if the drug can shrink the tumor or slow its growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.